Thrivent Financial for Lutherans’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Thrivent Financial for Lutherans’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-30,726	Closed	-$2.45M	–	2521
2022 Q2	$2.45M	Buy	+30,726	New	+$2.91M	0.01%	1117
2021 Q3	–	Sell	-32,950	Closed	-$3.08M	–	2527
2021 Q2	$3.08M	Buy	+32,950	New	+$3.03M	0.01%	1158
2020 Q2	–	Sell	-49,130	Closed	-$1.46M	–	2336
2020 Q1	$1.46M	Sell	49,130 -35,310	-42%	-$1.19M	0.01%	1103
2019 Q4	$3.06M	Sell	84,440 -10,290	-11%	-$316K	0.01%	852
2019 Q3	$2.58M	Sell	94,730 -8,470	-8%	-$219K	0.01%	873
2019 Q2	$2.48M	Buy	103,200 +60,060	+139%	+$1.52M	0.01%	890
2019 Q1	$1.14M	Buy	43,140 +19,690	+84%	+$467K	﹤0.01%	1288
2018 Q4	$458K	Buy	+23,450	New	+$460K	﹤0.01%	1624

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Thrivent Financial for Lutherans's HZNP Position: Q3 2022 in Review

Thrivent Financial for Lutherans sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q3 2022, closing a stake of 30,726 shares — an estimated $2.45M sold.

Thrivent Financial for Lutherans first reported a position in HZNP in Q4 2018 and held it in 8 quarters. The position peaked at $3.08M in Q2 2021. 530 funds tracked by Wall St. Rank hold HZNP as of Q3 2022.

Thrivent Financial for Lutherans reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q3 2022 after selling out during the quarter.
Thrivent Financial for Lutherans sold 30,726 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q3 2022, an estimated $2.45M.
Thrivent Financial for Lutherans first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2018 and held it in 8 quarters.
Thrivent Financial for Lutherans's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $3.08M in Q2 2021.
530 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q3 2022.

Based on Thrivent Financial for Lutherans's 13F filing for Q3 2022, filed 14 Nov 2022.